• Corporate
• Markets
• Info-Tech
• Marketing
• Money & Banking
• Agri-Biz & Commodities
• Industry & Economy
• Logistics
• Government
• Opinion
• Corporate Results
• Columns
• States
• Web Extras
• Index

• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books
• Gallery

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

• Rates

• Ports

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Subscription

• Business Line

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

NEW DELHI: Ranbaxy Laboratories on Monday said it has received the final approval of the Canadian drug regulator Therapeutic Products Directorate (TPD) to market and manufacture 'Ran-Amlodipine tablets', used in treating hypertensions.

The company has got the approval for Ran-Amlodipine (Amlodipine Besylate tablets) in 5 and 10 mg strengths, through its wholly-owned subsidiary Ranbaxy Pharmaceuticals- Canada Inc (RPCI), Gurgaon-based (RPCI) said in a statement.

"We look forward to marketing both strengths of Ran-Amlodipine tablets at an affordable prices that will be beneficial to both the Canadian healthcare system, and most importantly to Canadian patients,'' RPCI President, Mr Paul Drake said. The total mar ket for Amlodipine Besylate tablets in Canada is 456 million Canadian dollars. - PTI

Prev: Rupee spurts by 52 paise vs dollar
Next: Zandu Pharma Q1 profit doubles

Copyright copy; 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line